Skip to main content
Home » Reports » Healthcare » Adult Malignant Glioma Therapeutics Market
ReesrachMoz Brochure Icon

Global Adult Malignant Glioma Therapeutics Market Analysis and Forecast 2022-2027

Report ID:614Healthcare223 pages

Adult Malignant Glioma Therapeutics Market Statistics

The global adult malignant glioma therapeutics market is expected to witness a staggering expansion with a 9.3% CAGR and reach the estimated valuation of USD 2,964.5mn by the end of the forecast years 2022 to 2027.

Malignant Glioma is the most common type of brain tumour which is critical to treat due to the least chances for survival.

The rising adoption of novel therapies is expected to drive the global adult malignant glioma therapeutics market during the forecast years.

The covid pandemic had dampened the adult malignant glioma therapeutics demand as the surgeries and chemotherapies had to be put on the back burner and prioritize covid cases.

Now, as the economies are trying to come back with resilience post covid, so is the adult malignant glioma market expected to make a come back fiercely and thrive in the future.

Global Adult Malignant Glioma Therapeutics Market Share By Region Type

Drivers and Restraints

The growing investment in the research and development in terms of targeted drug development and novel therapies is expected to boost the growth of the global adult malignant glioma therapeutics market in the following years.

The availability of advanced imaging technologies for the early detection of the disease is anticipated to drive the global adult malignant glioma therapeutics market in the coming years.

Improvement in the survival rate due to the advancement in targeted therapies is likely to augment the demand for the adult malignant glioma therapeutics market during the forecast period.

The high usage of treatment therapies such as EGFR targeted therapies and tyrosine receptors are expected to bolster the demand in the global adult malignant glioma therapeutics market in the coming years.

However, the side effects associated with the treatment therapies are expected to hinder the growth of the global adult malignant glioma therapeutics during the forecast period.

Further, the high cost of treatment is expected to dampen the demand for the adult malignant glioma therapeutics market in the coming years.

Despite the constraint, the global adult malignant glioma therapeutics, the new imaging methods using the infra-red camera in integration with an imaging reagent tozuleristide (BLZ-100) which helps in retaining the healthy tissues in the area around the tumor is expected to proliferate the demand in the global adult malignant glioma therapeutics market in the following years.

Opportunities and Trends

The rising research and development in the medical sector are expected to drive growth opportunities in the global adult malignant glioma market during the forecast period.

The government support for the novel drug development is paving the way for the growth in the global adult glioma therapeutics market in the following years.

The use of cerebral organoids in the study of human malignant gliomas is gaining traction in recent times, thus resulting in growth opportunities in the global adult malignant therapeutics market in the coming years.

Product Segmentation

The global adult malignant glioma therapeutics market is segmented into anaplastic astrocytoma, glioblastoma multiforme, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others.

Of these, the glioblastoma multiforme is expected to hold a major share in the global adult malignant therapeutics, owing to the significant amount of patient population needing therapies in the years to come.

Based on therapy, the adult malignant glioma therapeutics market is classified into targeted drug therapy, chemotherapy, and radiation drug therapies.

Further, the chemotherapy is segmented into bevacizumab, temozolomide, carmustine, and others and the targeted therapy is classified into – monoclonal antibodies inhibitors.

It is the targeted therapy which is expected to dominate the therapeutics segment during the forecast period, owing to novel therapies in the pipeline.

In terms of end-users, the global adult malignant glioma market is divided into- hospitals, clinics, cancer and radiation therapy centres, and others.

Cancer and radiation therapy centres will thrive in the global adult malignant therapeutics market, owing to the increasing number of adult glioma cases.

Regional Overview

On the basis of region, the global adult malignant therapeutics market is expected to be dominated by the Asia Pacific, especially in developing countries. The growth in the region can be attributed to a high volume of patients and better healthcare facilities at affordable prices.

The increasing focus on improved healthcare infrastructure is paving way for early diagnosis, further resulting in the region expanding during the forecast period.

Previously, North America held a larger share in adult malignant glioma therapeutics owing to the technological advancements in the region.

Competitive Landscape

The global adult malignant glioma market has some international players which include-

  • Arbor Pharmaceuticals,
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd
  • Sun Pharmaceuticals Ltd
  • Emcure Pharmaceuticals Limited.
  • Bristol-Myers Squibb Company
  • Amgen Inc.

Disease Type Disposition (USD Revenues in Millions)

  • Anaplastic Astrocytoma,
  • Glioblastoma Multiforme,
  • Anaplastic Oligodendroglioma,
  • Anaplastic oligoastrocytoma,
  • Others

Therapy Type Disposition (USD Revenues in Millions)

  • Targeted Therapies
  • Chemo Therapy
  • Radiation Therapy
  • Others

Regional Disposition

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions-

  1. What positive impact would the adult malignant glioma therapeutics market have during the forecast period?
  2. Which region would hold the largest share in the global adult malignant glioma therapeutics market?
  3. What the growth opportunities would the global adult malignant glioma therapeutics market in the coming years?
  4. How would the market behave during the forecast period and what is the expected growth rate?

Table Of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics

4. Global Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis

5. Global Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type Disposition
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Disease Type Disposition, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Disease Type Disposition, 2022-2032
5.3.1. Anaplastic Astrocytoma
5.3.2. Glioblastoma Multiforme
5.3.3. Anaplastic Oligodendroglioma
5.3.4. Anaplastic oligoastrocytoma
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Disease Type Disposition, 2017-2021
5.5. Absolute $ Opportunity Analysis By Disease Type Disposition, 2022-2032

6. Global Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type Disposition
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Therapy Type Disposition, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Therapy Type Disposition, 2022-2032
6.3.1. Targeted Therapies
6.3.2. Chemo Therapy
6.3.3. Radiation Therapy
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Therapy Type Disposition, 2017-2021
6.5. Absolute $ Opportunity Analysis By Therapy Type Disposition, 2022-2032

7. Global Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region

8. North America Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Disease Type Disposition
8.2.3. By Therapy Type Disposition
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Disease Type Disposition
8.3.3. By Therapy Type Disposition
8.4. Key Takeaways

9. Latin America Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Chile
9.2.1.5. Peru
9.2.1.6. Rest of Latin America
9.2.2. By Disease Type Disposition
9.2.3. By Therapy Type Disposition
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type Disposition
9.3.3. By Therapy Type Disposition
9.4. Key Takeaways

10. Europe Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Disease Type Disposition
10.2.3. By Therapy Type Disposition
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type Disposition
10.3.3. By Therapy Type Disposition
10.4. Key Takeaways

11. East Asia Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Disease Type Disposition
11.2.3. By Therapy Type Disposition
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type Disposition
11.3.3. By Therapy Type Disposition
11.4. Key Takeaways

12. South Asia Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By Disease Type Disposition
12.2.3. By Therapy Type Disposition
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type Disposition
12.3.3. By Therapy Type Disposition
12.4. Key Takeaways

13. Oceania Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Disease Type Disposition
13.2.3. By Therapy Type Disposition
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type Disposition
13.3.3. By Therapy Type Disposition
13.4. Key Takeaways

14. MEA Adult Malignant Glioma Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By Disease Type Disposition
14.2.3. By Therapy Type Disposition
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type Disposition
14.3.3. By Therapy Type Disposition
14.4. Key Takeaways

15. Key Countries Adult Malignant Glioma Therapeutics Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Disease Type Disposition
15.1.2.2. By Therapy Type Disposition
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Disease Type Disposition
15.2.2.2. By Therapy Type Disposition
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Disease Type Disposition
15.3.2.2. By Therapy Type Disposition
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Disease Type Disposition
15.4.2.2. By Therapy Type Disposition
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Disease Type Disposition
15.5.2.2. By Therapy Type Disposition

16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1.  By Regional
16.3.2.  By Disease Type Disposition
16.3.3.  By Therapy Type Disposition

17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Arbor Pharmaceuticals,
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Pfizer, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Merck & Co., Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. F. Hoffmann-La Roche Ltd
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Sun Pharmaceuticals Ltd
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Emcure Pharmaceuticals Limited.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Bristol-Myers Squibb Company
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Amgen Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Request Free Sample

Hidden
Hidden

Company logos Strips